Royal Bank Of Canada Issues Positive Forecast for Charles River Laboratories International (NYSE:CRL) Stock Price

Charles River Laboratories International (NYSE:CRL) had its price target raised by stock analysts at Royal Bank Of Canada from $282.00 to $322.00 in a report issued on Friday, Benzinga reports. The brokerage presently has an “outperform” rating on the medical research company’s stock. Royal Bank Of Canada’s target price would indicate a potential upside of 10.64% from the stock’s current price.

Several other brokerages have also weighed in on CRL. Weiss Ratings upgraded Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 1st. Piper Sandler set a $300.00 target price on Charles River Laboratories International in a report on Monday, August 10th. Evercore reiterated an “outperform” rating and issued a $320.00 price target on shares of Charles River Laboratories International in a research report on Friday, September 11th. Citigroup reissued a “buy” rating on shares of Charles River Laboratories International in a report on Wednesday, July 8th. Finally, TD Cowen restated a “buy” rating on shares of Charles River Laboratories International in a research report on Friday. Eleven investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Charles River Laboratories International presently has an average rating of “Moderate Buy” and an average price target of $282.81.

Charles River Laboratories International Price Performance

Shares of NYSE:CRL opened at $291.03 on Friday. Charles River Laboratories International has a 12 month low of $145.32 and a 12 month high of $303.30. The stock has a market cap of $13.89 billion, a price-to-earnings ratio of -59.72, a PEG ratio of 2.80 and a beta of 1.40. The stock’s 50 day moving average price is $269.08 and its 200 day moving average price is $212.48. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $980.53 million. During the same period last year, the company posted $3.12 EPS. The firm’s quarterly revenue was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Equities research analysts anticipate that Charles River Laboratories International will post 11.33 earnings per share for the current fiscal year.

Insider Activity at Charles River Laboratories International

In other news, CEO Birgit Girshick sold 6,500 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $279.90, for a total transaction of $1,819,350.00. Following the completion of the sale, the chief executive officer directly owned 36,013 shares of the company’s stock, valued at $10,080,038.70. This represents a 15.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nancy C. Andrews sold 573 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $285.24, for a total value of $163,442.52. Following the completion of the transaction, the director owned 1,438 shares of the company’s stock, valued at $410,175.12. This trade represents a 28.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 165,990 shares of company stock valued at $42,606,388 over the last ninety days. Company insiders own 1.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in CRL. Continuum Advisory LLC purchased a new position in Charles River Laboratories International during the 2nd quarter worth approximately $30,000. SHP Wealth Management purchased a new stake in shares of Charles River Laboratories International in the fourth quarter valued at $85,000. Eurizon Capital SGR S.p.A. purchased a new stake in shares of Charles River Laboratories International in the fourth quarter valued at $104,000. Hilltop National Bank boosted its position in shares of Charles River Laboratories International by 28.7% in the second quarter. Hilltop National Bank now owns 569 shares of the medical research company’s stock worth $129,000 after buying an additional 127 shares during the period. Finally, Trust Asset Management LLC acquired a new stake in shares of Charles River Laboratories International in the second quarter worth $129,000. 98.91% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Charles River Laboratories International

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Charles River reaffirmed its fiscal 2026 revenue outlook of approximately $3.9 billion and raised its EPS guidance to $11.45, modestly above the analyst consensus of $11.33. Charles River sets 2030 targets, lifts 2026 earnings outlook
• Positive Sentiment: At Investor Day, management outlined 2030 growth objectives that imply stronger revenue and earnings expansion over the long term. The targets, together with the reaffirmed 2026 outlook, prompted a sharp rise in the stock as investors responded favorably to the company’s strategy and earnings potential. Charles River Stock Rises After Unveiling 2030 Growth Targets
• Positive Sentiment: Robert W. Baird raised its price target from $291 to $334 and maintained an “outperform” rating, citing additional upside following the Investor Day update. Baird price-target update
• Neutral Sentiment: Mizuho increased its price target from $264 to $295 but retained a “neutral” rating. The limited implied upside suggests the firm views much of the favorable Investor Day news as already reflected in CRL’s elevated share price. Mizuho price-target update
• Negative Sentiment: A Seeking Alpha analysis argued that the positive Investor Day announcements are “fully priced in,” raising concerns that the stock’s valuation leaves less room for further gains unless Charles River delivers on its long-term targets. Positive Investor Day Is Fully Priced In

About Charles River Laboratories International

Charles River Laboratories International, Inc is a global provider of drug discovery, nonclinical development and laboratory services for pharmaceutical, biotechnology and medical device companies, as well as academic and government research institutions. The company supports customers throughout the development process, from early-stage research and target identification through preclinical testing and regulatory preparation.

Its offerings include research models and related products, discovery and development services, toxicology and safety assessment, efficacy testing, bioanalysis, and laboratory testing.